Search Results - "Teo, Min Yuen"

Treatment of Advanced Prostate Cancer by Teo, Min Yuen, Rathkopf, Dana E, Kantoff, Philip

“…The therapeutic landscape of prostate cancer has been transformed over the last decade by new therapeutics, advanced functional imaging, next-generation…”
Get full text

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients by Nguyen, Bastien, Fong, Christopher, Luthra, Anisha, Smith, Shaleigh A., DiNatale, Renzo G., Nandakumar, Subhiksha, Walch, Henry, Chatila, Walid K., Madupuri, Ramyasree, Kundra, Ritika, Bielski, Craig M., Mastrogiacomo, Brooke, Donoghue, Mark T.A., Boire, Adrienne, Chandarlapaty, Sarat, Ganesh, Karuna, Harding, James J., Iacobuzio-Donahue, Christine A., Razavi, Pedram, Reznik, Ed, Rudin, Charles M., Zamarin, Dmitriy, Abida, Wassim, Abou-Alfa, Ghassan K., Aghajanian, Carol, Cercek, Andrea, Chi, Ping, Feldman, Darren, Ho, Alan L., Iyer, Gopakumar, Janjigian, Yelena Y., Morris, Michael, Motzer, Robert J., O’Reilly, Eileen M., Postow, Michael A., Raj, Nitya P., Riely, Gregory J., Robson, Mark E., Rosenberg, Jonathan E., Safonov, Anton, Shoushtari, Alexander N., Tap, William, Teo, Min Yuen, Varghese, Anna M., Voss, Martin, Yaeger, Rona, Zauderer, Marjorie G., Abu-Rustum, Nadeem, Garcia-Aguilar, Julio, Bochner, Bernard, Hakimi, Abraham, Jarnagin, William R., Jones, David R., Molena, Daniela, Morris, Luc, Rios-Doria, Eric, Russo, Paul, Singer, Samuel, Strong, Vivian E., Chakravarty, Debyani, Ellenson, Lora H., Gopalan, Anuradha, Reis-Filho, Jorge S., Weigelt, Britta, Ladanyi, Marc, Gonen, Mithat, Shah, Sohrab P., Massague, Joan, Gao, Jianjiong, Zehir, Ahmet, Berger, Michael F., Solit, David B., Bakhoum, Samuel F., Sanchez-Vega, Francisco, Schultz, Nikolaus

“…Metastatic progression is the main cause of death in cancer patients, whereas the underlying genomic mechanisms driving metastasis remain largely unknown…”
Get full text

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers by Teo, Min Yuen, Seier, Kenneth, Ostrovnaya, Irina, Regazzi, Ashley M, Kania, Brooke E, Moran, Meredith M, Cipolla, Catharine K, Bluth, Mark J, Chaim, Joshua, Al-Ahmadie, Hikmat, Snyder, Alexandra, Carlo, Maria I, Solit, David B, Berger, Michael F, Funt, Samuel, Wolchok, Jedd D, Iyer, Gopa, Bajorin, Dean F, Callahan, Margaret K, Rosenberg, Jonathan E

“…Purpose Alterations in DNA damage response and repair (DDR) genes are associated with increased mutation load and improved clinical outcomes in…”
Get full text

The landscape of immunotherapy in metastatic urothelial carcinoma by Teo, Min Yuen, Iyer, Gopa

“…PURPOSE OF REVIEWThis review provides an overview of clinical trials recently completed or currently ongoing evaluating the role of checkpoint blockade in…”
Get full text

Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy by Pietzak, Eugene J., Zabor, Emily C., Bagrodia, Aditya, Armenia, Joshua, Hu, Wenhuo, Zehir, Ahmet, Funt, Samuel, Audenet, Francois, Barron, David, Maamouri, Noelia, Li, Qiang, Teo, Min Yuen, Arcila, Maria E., Berger, Michael F., Schultz, Nikolaus, Dalbagni, Guido, Herr, Harry W., Bajorin, Dean F., Rosenberg, Jonathan E., Al-Ahmadie, Hikmat, Bochner, Bernard H., Solit, David B., Iyer, Gopa

“…Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard of care for patients with muscle-invasive bladder cancer…”
Get full text

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC) by Teo, Min Yuen, Scher, Howard I.

“…Summary Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen…”
Get full text

Cancer Susceptibility Mutations in Patients With Urothelial Malignancies by Carlo, Maria I, Ravichandran, Vignesh, Srinavasan, Preethi, Bandlamudi, Chaitanya, Kemel, Yelena, Ceyhan-Birsoy, Ozge, Mukherjee, Semanti, Mandelker, Diana, Chaim, Joshua, Knezevic, Andrea, Rana, Satshil, Fnu, Zarina, Breen, Kelsey, Arnold, Angela G, Khurram, Aliya, Tkachuk, Kaitlyn, Cipolla, Catharine K, Regazzi, Ashley, Hakimi, A Ari, Al-Ahmadie, Hikmat, Dalbagni, Guido, Cadoo, Karen A, Walsh, Michael F, Teo, Min-Yuen, Funt, Samuel A, Coleman, Jonathan A, Bochner, Bernard H, Iyer, Gopa, Solit, David B, Stadler, Zsofia K, Zhang, Liying, Rosenberg, Jonathan E, Taylor, Barry S, Robson, Mark E, Berger, Michael F, Vijai, Joseph, Bajorin, Dean F, Offit, Kenneth

“…Urothelial cancers (UCs) have a substantial hereditary component, but, other than their association with Lynch syndrome, the contribution of genetic risk…”
Get full text

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer by Liu, David, Abbosh, Philip, Keliher, Daniel, Reardon, Brendan, Miao, Diana, Mouw, Kent, Weiner-Taylor, Amaro, Wankowicz, Stephanie, Han, Garam, Teo, Min Yuen, Cipolla, Catharine, Kim, Jaegil, Iyer, Gopa, Al-Ahmadie, Hikmat, Dulaimi, Essel, Chen, David Y. T., Alpaugh, R. Katherine, Hoffman-Censits, Jean, Garraway, Levi A., Getz, Gad, Carter, Scott L., Bellmunt, Joaquim, Plimack, Elizabeth R., Rosenberg, Jonathan E., Van Allen, Eliezer M.

“…Despite continued widespread use, the genomic effects of cisplatin-based chemotherapy and implications for subsequent treatment are incompletely characterized…”
Get full text

EMA and FDA prune the checkpoint inhibitor treatment landscape by Teo, Min Yuen, Rosenberg, Jonathan E.

“…The European Medicines Agency (EMA) and FDA have recently restricted the indications for first-line pembrolizumab and atezolizumab to patients with programmed…”
Get full text

Refining existing knowledge and management of bladder cancer by Teo, Min Yuen, Rosenberg, Jonathan E.

“…For the management of bladder cancer, 2018 has been characterized by deepened knowledge on the molecular basis of invasive bladder cancer and its potential…”
Get full text

FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation by Warrick, Joshua I., Hu, Wenhuo, Yamashita, Hironobu, Walter, Vonn, Shuman, Lauren, Craig, Jenna M., Gellert, Lan L., Castro, Mauro A. A., Robertson, A. Gordon, Kuo, Fengshen, Ostrovnaya, Irina, Sarungbam, Judy, Chen, Ying-bei, Gopalan, Anuradha, Sirintrapun, Sahussapont J., Fine, Samson W., Tickoo, Satish K., Kim, Kwanghee, Thomas, Jasmine, Karan, Nagar, Gao, Sizhi Paul, Clinton, Timothy N., Lenis, Andrew T., Chan, Timothy A., Chen, Ziyu, Rao, Manisha, Hollman, Travis J., Li, Yanyun, Socci, Nicholas D., Chavan, Shweta, Viale, Agnes, Mohibullah, Neeman, Bochner, Bernard H., Pietzak, Eugene J., Teo, Min Yuen, Iyer, Gopa, Rosenberg, Jonathan E., Bajorin, Dean F., Kaag, Matthew, Merrill, Suzanne B., Joshi, Monika, Adam, Rosalyn, Taylor, John A., Clark, Peter E., Raman, Jay D., Reuter, Victor E., Chen, Yu, Funt, Samuel A., Solit, David B., DeGraff, David J., Al-Ahmadie, Hikmat A.

“…Cancers arising from the bladder urothelium often exhibit lineage plasticity with regions of urothelial carcinoma adjacent to or admixed with regions of…”
Get full text

Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis by O'Reilly, David, O'Leary, Caroline L, Reilly, Aislinn, Teo, Min Yuen, O'Kane, Grainne, Hendriks, Lizza, Bennett, Kathleen, Naidoo, Jarushka

“…The combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) can be associated with significant toxicity. We performed a…”
Get full text

Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI by Woo, Sungmin, Becker, Anton S., Das, Jeeban P., Ghafoor, Soleen, Arita, Yuki, Benfante, Nicole, Gangai, Natalie, Teo, Min Yuen, Goh, Alvin C., Vargas, Hebert A.

“…Abstract Background Neoadjuvant chemotherapy (NAC) before radical cystectomy is standard of care in patients with muscle-invasive bladder cancer (MIBC)…”
Get full text

Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma by Teo, Min Yuen, MD, Rosenberg, Jonathan E., MD

“…Neoadjuvant chemotherapy improves survival in patients with muscle-invasive bladder cancer. However, a significant proportion of patients are ineligible for…”
Get full text

Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation by Warrick, Joshua I., Hu, Wenhuo, Yamashita, Hironobu, Walter, Vonn, Shuman, Lauren, Craig, Jenna M., Gellert, Lan L., Castro, Mauro A. A., Robertson, A. Gordon, Kuo, Fengshen, Ostrovnaya, Irina, Sarungbam, Judy, Chen, Ying-bei, Gopalan, Anuradha, Sirintrapun, Sahussapont J., Fine, Samson W., Tickoo, Satish K., Kim, Kwanghee, Thomas, Jasmine, Karan, Nagar, Gao, Sizhi Paul, Clinton, Timothy N., Lenis, Andrew T., Chan, Timothy A., Chen, Ziyu, Rao, Manisha, Hollman, Travis J., Li, Yanyun, Socci, Nicholas D., Chavan, Shweta, Viale, Agnes, Mohibullah, Neeman, Bochner, Bernard H., Pietzak, Eugene J., Teo, Min Yuen, Iyer, Gopa, Rosenberg, Jonathan E., Bajorin, Dean F., Kaag, Matthew, Merrill, Suzanne B., Joshi, Monika, Adam, Rosalyn, Taylor, John A., Clark, Peter E., Raman, Jay D., Reuter, Victor E., Chen, Yu, Funt, Samuel A., Solit, David B., DeGraff, David J., Al-Ahmadie, Hikmat A.

Get full text

Drug development for noncastrate prostate cancer in a changed therapeutic landscape by Teo, Min Yuen, O'Shaughnessy, Matthew J., McBride, Sean M., Vargas, Herbert A., Scher, Howard I.

“…Key Points The increasing number of both approved and experimental therapies available mandates the use of new trial designs for patients with noncastrate…”
Get full text

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy by Ged, Yasser, Chaim, Joshua L, DiNatale, Renzo G, Knezevic, Andrea, Kotecha, Ritesh R, Carlo, Maria I, Lee, Chung-Han, Foster, Ashley, Feldman, Darren R, Teo, Min Yuen, Iyer, Gopakumar, Chan, Timothy, Patil, Sujata, Motzer, Robert J, Hakimi, A Ari, Voss, Martin H

“…BackgroundLoss-of-function alterations in DNA damage repair (DDR) genes are associated with human tumorigenesis and may determine benefit from immune-oncology…”
Get full text

Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma by Mar, Nataliya, Zakharia, Yousef, Falcon, Alejandro, Morales-Barrera, Rafael, Mellado, Begona, Duran, Ignacio, Oh, Do-Youn, Williamson, Stephen K, Gajate, Pablo, Arkenau, Hendrik-Tobias, Jones, Robert J, Teo, Min Yuen, Turan, Tolga, McLaughlin, Robert T, Peltier, Hillary M, Chong, Elizabeth, Atluri, Harisha, Dean, James P, Castellano, Daniel

“…Ibrutinib is a first-in-class Bruton's tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies and chronic graft-versus-host…”
Get full text

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract by Sarfaty, Michal, Whiting, Karissa, Teo, Min Yuen, Lee, Chung‐Han, Peters, Vanessa, Durocher, Jennifer, Regazzi, Ashley M., McCoy, Asia S., Hettich, Grace, Jungbluth, Achim A., Al‐Ahmadie, Hikmat, Ostrovnaya, Irina, Chaim, Joshua, Bajorin, Dean F., Rosenberg, Jonathan E., Iyer, Gopa, Funt, Samuel A.

“…Background Immune checkpoint blockade has made a significant impact on the clinical outcomes of patients with metastatic urothelial carcinoma (UC). However,…”
Get full text

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis by Chandran, Elias B A, Iannantuono, Giovanni Maria, Atiq, Saad O, Akbulut, Dilara, Sinaii, Ninet, Simon, Nicholas I, Banday, Abdul Rouf, Boudjadi, Salah, Gurram, Sandeep, Nassar, Amin H, Rosenberg, Jonathan E, Butera, Gisela, Teo, Min Yuen, Sonpavde, Guru, Coleman, Jonathan A, Apolo, Andrea B

“…BackgroundMismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) occur in a subset of cancers and have been shown to confer sensitivity…”
Get full text